(DOCS) Doximity - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 4.287m USD | Total Return: -57.1% in 12m

Platform, Software, Solutions, Tools
Total Rating 37
Safety 87
Buy Signal -1.53
Health Information Services
Industry Rotation: -3.9
Market Cap: 4.29B
Avg Turnover: 53.8M USD
ATR: 5.04%
Peers RS (IBD): 9.4
Risk 5d forecast
Volatility58.3%
Rel. Tail Risk-24.2%
Reward TTM
Sharpe Ratio-1.53
Alpha-96.41
Character TTM
Beta1.670
Beta Downside1.842
Drawdowns 3y
Max DD72.94%
CAGR/Max DD-0.19
EPS (Earnings per Share) EPS (Earnings per Share) of DOCS over the last years for every Quarter: "2021-03": 0.06, "2021-06": 0.11, "2021-09": 0.19, "2021-12": 0.29, "2022-03": 0.21, "2022-06": 0.14, "2022-09": 0.17, "2022-12": 0.22, "2023-03": 0.2, "2023-06": 0.19, "2023-09": 0.22, "2023-12": 0.29, "2024-03": 0.25, "2024-06": 0.28, "2024-09": 0.3, "2024-12": 0.45, "2025-03": 0.38, "2025-06": 0.36, "2025-09": 0.45, "2025-12": 0.46, "2026-03": 0,
EPS CAGR: -38.74%
EPS Trend: 44.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of DOCS over the last years for every Quarter: 2021-03: 66.687, 2021-06: 72.669, 2021-09: 79.35, 2021-12: 97.876, 2022-03: 93.653, 2022-06: 90.639, 2022-09: 102.185, 2022-12: 115.262, 2023-03: 110.966, 2023-06: 108.469, 2023-09: 113.612, 2023-12: 135.284, 2024-03: 118.057, 2024-06: 126.676, 2024-09: 136.832, 2024-12: 168.603, 2025-03: 138.288, 2025-06: 145.913, 2025-09: 168.525, 2025-12: 185.053, 2026-03: null,
Rev. CAGR: 19.91%
Rev. Trend: 94.0%
Last SUE: 0.72
Qual. Beats: 0

Warnings

Volatile

Tailwinds

No distinct edge detected

Description: DOCS Doximity

Doximity, Inc. (NYSE: DOCS) operates a U.S.-focused digital platform that equips physicians, nurse practitioners, physician assistants, medical students, pharma firms, and health systems with tools for collaboration, news aggregation, career management, on-call scheduling, documentation, and virtual patient visits.

Since its 2010 incorporation (formerly 3MD Communications), the company has grown its member base to over 2.2 million active clinicians, representing roughly 85 % of U.S. physicians, and generated FY 2025 revenue of $1.12 billion-a 27 % year-over-year increase driven by higher subscription uptake and expanding telehealth services.

Key sector dynamics supporting Doximity include sustained growth in healthcare IT spending (projected CAGR of 9 % through 2028) and the continued normalization of virtual care, which together boost demand for integrated digital workflow solutions.

Analysts note that Doximity’s adjusted EBITDA margin has risen to 21 % in FY 2025, reflecting improved monetization of its professional network and cost efficiencies from its cloud-native architecture.

For deeper quantitative analysis, you might explore the valuation metrics on ValueRay.

Headlines to Watch Out For
  • Pharmaceutical advertising spend directly impacts Doximitys revenue growth
  • Healthcare system adoption of telehealth services drives platform usage
  • Physician engagement with digital tools influences subscription renewals
  • Regulatory changes in telehealth reimbursement affect platform utilization
Piotroski VR‑10 (Strict) 6.5
Net Income: 239.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.27 > 0.02 and ΔFCF/TA 7.13 > 1.0
NWC/Revenue: 132.3% < 20% (prev 163.0%; Δ -30.74% < -1%)
CFO/TA 0.27 > 3% & CFO 315.4m > Net Income 239.4m
Net Debt (-724.4m) to EBITDA (272.4m): -2.66 < 3
Current Ratio: 6.63 > 1.5 & < 3
Outstanding Shares: last quarter (199.2m) vs 12m ago -1.49% < -2%
Gross Margin: 89.75% > 18% (prev 0.90%; Δ 8.88k% > 0.5%)
Asset Turnover: 54.76% > 50% (prev 46.94%; Δ 7.83% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 6.46
A: 0.73 (Total Current Assets 993.5m - Total Current Liabilities 149.8m) / Total Assets 1.16b
B: 0.02 (Retained Earnings 21.0m / Total Assets 1.16b)
C: 0.22 (EBIT TTM 257.7m / Avg Total Assets 1.16b)
D: 0.13 (Book Value of Equity 22.6m / Total Liabilities 177.7m)
Altman-Z'' Score: 6.46 = AAA
Beneish M -2.97
DSRI: 0.98 (Receivables 156.6m/137.5m, Revenue 637.8m/550.2m)
GMI: 1.00 (GM 89.75% / 90.19%)
AQI: 1.03 (AQ_t 0.12 / AQ_t-1 0.12)
SGI: 1.16 (Revenue 637.8m / 550.2m)
TATA: -0.07 (NI 239.4m - CFO 315.4m) / TA 1.16b)
Beneish M-Score: -2.97 (Cap -4..+1) = A
What is the price of DOCS shares? As of April 08, 2026, the stock is trading at USD 22.50 with a total of 1,602,483 shares traded.
Over the past week, the price has changed by -3.43%, over one month by -11.73%, over three months by -51.60% and over the past year by -57.05%.
Is DOCS a buy, sell or hold? Doximity has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold DOCS.
  • StrongBuy: 5
  • Buy: 3
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DOCS price?
Analysts Target Price 39.6 75.8%
Doximity (DOCS) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 19.1345
P/E Forward = 14.4092
P/S = 6.7217
P/B = 4.2947
P/EG = 0.6266
Revenue TTM = 637.8m USD
EBIT TTM = 257.7m USD
EBITDA TTM = 272.4m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -724.4m USD (recalculated: Debt 10.7m - CCE 735.1m)
Enterprise Value = 3.56b USD (4.29b + Debt 10.7m - CCE 735.1m)
 Interest Coverage Ratio = unknown (Ebit TTM 257.7m / Interest Expense TTM 0.0)
 EV/FCF = 11.43x (Enterprise Value 3.56b / FCF TTM 311.5m)
FCF Yield = 8.75% (FCF TTM 311.5m / Enterprise Value 3.56b)
FCF Margin = 48.85% (FCF TTM 311.5m / Revenue TTM 637.8m)
Net Margin = 37.54% (Net Income TTM 239.4m / Revenue TTM 637.8m)
Gross Margin = 89.75% ((Revenue TTM 637.8m - Cost of Revenue TTM 65.4m) / Revenue TTM)
Gross Margin QoQ = 89.89% (prev 90.25%)
Tobins Q-Ratio = 3.08 (Enterprise Value 3.56b / Total Assets 1.16b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.7m)
Taxrate = 23.81% (19.2m / 80.8m)
NOPAT = 196.3m (EBIT 257.7m * (1 - 23.81%))
Current Ratio = 6.63 (Total Current Assets 993.5m / Total Current Liabilities 149.8m)
Debt / Equity = 0.01 (Debt 10.7m / totalStockholderEquity, last quarter 979.3m)
Debt / EBITDA = -2.66 (Net Debt -724.4m / EBITDA 272.4m)
Debt / FCF = -2.33 (Net Debt -724.4m / FCF TTM 311.5m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.56% (Net Income 239.4m / Total Assets 1.16b)
RoE = 22.89% (Net Income TTM 239.4m / Total Stockholder Equity 1.05b)
RoCE = 24.39% (EBIT 257.7m / Capital Employed (Equity 1.05b + L.T.Debt 10.7m))
RoIC = 18.77% (NOPAT 196.3m / Invested Capital 1.05b)
WACC = 11.83% (E(4.29b)/V(4.30b) * Re(11.86%) + D(10.7m)/V(4.30b) * Rd(0.0%) * (1-Tc(0.24)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF] Terminal Value 70.12% ; FCFF base≈279.8m ; Y1≈345.1m ; Y5≈588.8m
[DCF] Fair Price = 47.27 (EV 5.60b - Net Debt -724.4m = Equity 6.32b / Shares 133.8m; r=11.83% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 44.37 | EPS CAGR: -38.74% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.97 | Revenue CAGR: 19.91% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-8 | Analysts=14
EPS next Year (2027-03-31): EPS=1.62 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-13 | Growth EPS=+5.0% | Growth Revenue=+9.0%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.6% (Discount Rate 11.9% - Earnings Yield 5.2%)
[Growth] Growth Spread = -1.3% (Analyst 5.3% - Implied 6.6%)
External Resources
Dataroma Stockcircle